Uncategorized

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the first results from the open-label Phase 2 SunRISe-1 study evaluating the efficacy and safety of TAR-200 monotherapy and cetrelimab monotherapy in patients with Bacillus Calmette-Guérin -unresponsive high-risk non-muscle-invasive bladder cancer, who are ineligible for, or decline, radical cystectomy.

As a next step in focusing on the US market The Board of Directors of Immunovia AB, has decided to appoint Jeff Borcherding, until now President of Immunovia’s US operation, as global CEO.

UroGen Pharma Ltd., a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, highlights the results of a sub-analysis from the first and largest post-commercial utilization review of JELMYTO® for pyelocalyceal solution presented at the American Urological Association Meeting 2023 in Chicago, IL.

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-001 for the treatment of advanced nonalcoholic steatohepatitis.

Pliant Therapeutics, Inc. announced 24-week data from the 320 mg dose group of INTEGRIS-IPF, a multinational, randomized, dose-ranging, double-blind, placebo-controlled Phase 2a clinical trial of bexotegrast in patients with idiopathic pulmonary fibrosis.

The American Urological Association announced that Pfizer Oncology is the recipient of the 2023 Health Science Award for its outstanding support of the educational, scientific and research goals of the AUA and the Urology Care Foundation in urologic cancer.

Aquavit Holdings announced that it has received FDA clearance to initiate clinical trials for DTX-023 and DTX-024, following its submission of Investigational New Drug Applications.

Astellas Pharma Inc. and Pfizer Inc. announced that XTANDI® plus leuprolide significantly reduced the risk of metastasis or death by 58% versus placebo plus leuprolide, as assessed by the primary endpoint of metastasis-free survival, in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and MedinCell announced that the U.S. Food and Drug Administration has approved UZEDY extended-release injectable suspension for the treatment of schizophrenia in adults.

The joint venture between Walgreens and Prothena to accelerate the approval of an Alzheimer’s treatment is the latest in biotech and retail chain alliances.